Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Huifeng Bio-Pharma Expects 50% Revenue Increase in 2010

publication date: Feb 5, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Huifeng Bio-Pharmaceutical Technology reported it expects 2009 revenues to be between $13 million and $14 million, about 30% better than last year. Net income is forecast to be as much as $3 million. The big news is that Huifeng predicts 2010’s revenues will be in a range between $20 million and $25 million, an increase of 50% or more. More details...

Stock Symbol: (OTCBB: HFGB)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...